- Home
- SUPN vs DFIN Comparison
SUPN vs DFIN Comparison
Compare SUPN & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- DFIN
- Stock Information
- Founded
- SUPN 2005
- DFIN 1983
- Country
- SUPN United States
- DFIN United States
- Employees
- SUPN N/A
- DFIN N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- DFIN Other Consumer Services
- Sector
- SUPN Health Care
- DFIN Consumer Discretionary
- Exchange
- SUPN Nasdaq
- DFIN Nasdaq
- Market Cap
- SUPN 1.9B
- DFIN 1.2B
- IPO Year
- SUPN 2012
- DFIN N/A
- Fundamental
- Price
- SUPN $31.89
- DFIN $61.85
- Analyst Decision
- SUPN Hold
- DFIN Strong Buy
- Analyst Count
- SUPN 2
- DFIN 3
- Target Price
- SUPN $36.00
- DFIN $68.67
- AVG Volume (30 Days)
- SUPN 672.1K
- DFIN 260.0K
- Earning Date
- SUPN 08-05-2025
- DFIN 07-30-2025
- Dividend Yield
- SUPN N/A
- DFIN N/A
- EPS Growth
- SUPN N/A
- DFIN N/A
- EPS
- SUPN 1.11
- DFIN 3.01
- Revenue
- SUPN $667,997,000.00
- DFIN $779,600,000.00
- Revenue This Year
- SUPN N/A
- DFIN $1.99
- Revenue Next Year
- SUPN $12.02
- DFIN $4.64
- P/E Ratio
- SUPN $28.74
- DFIN $20.48
- Revenue Growth
- SUPN 11.82
- DFIN N/A
- 52 Week Low
- SUPN $25.55
- DFIN $37.80
- 52 Week High
- SUPN $40.28
- DFIN $71.01
- Technical
- Relative Strength Index (RSI)
- SUPN 43.90
- DFIN 74.96
- Support Level
- SUPN $30.93
- DFIN $60.32
- Resistance Level
- SUPN $31.81
- DFIN $62.27
- Average True Range (ATR)
- SUPN 0.94
- DFIN 1.20
- MACD
- SUPN -0.13
- DFIN 0.04
- Stochastic Oscillator
- SUPN 25.44
- DFIN 89.74
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.